Imbach P Kühne T 1998 Immune thrombocytopenic purpura ITP is characterized by early platelet destruction due to an imbalanced immune response. In acute ITP, a transient increase of HLA-DR molecules has been detected while in individuals with chronic ITP, in addition, increased serum concentrations of IL-2 and other cytokines reflecting in vivo T-cell activation have been observed. Clinically, the hemorrhagic manifestation of ITP rather than the platelet count should define the indication for active intervention. In a staging system a patient with stage III has bleeding signs and platelet counts below 10 or 20 x 10(9)/L and needs treatment, a patient with stage II should be treated on an individual level (prevention of bleeding) and a patient with stage I (no bleeding, platelet count above 50 x 10(9)/L) should be observed only. https://sonar.ch/global/documents/164831 eng info:eu-repo/semantics/altIdentifier/doi/10.1111/j.1423-0410.1998.tb05436.x info:eu-repo/semantics/altIdentifier/pmid/9704461 Vox sanguinis. - 1998 Adolescent Adult Antigens, Human Platelet Autoantibodies Autoimmune Diseases Blood Platelets Child Child, Preschool Combined Modality Therapy Female Hemorrhagic Disorders Humans Immunity, Maternally-Acquired Immunoglobulins, Intravenous Immunologic Factors Immunosuppressive Agents Infant Infant, Newborn Infections Interferon-alpha Isoantibodies Male Phagocytosis Pregnancy Purpura, Thrombocytopenic, Idiopathic Remission, Spontaneous Splenectomy Transfusion Reaction Immune thrombocytopenic purpura ITP. http://purl.org/coar/resource_type/c_6501